<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>Wuxi Healthcare Forum</title>
    <description></description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Don’t repurpose, but develop better drugs, experts say</title>
      <description>BEIJING – While repurposing drugs may be a quick solution to an epidemic like COVID-19 that has a limited research window, it’s just luck as to whether an already available drug candidate exists for newly emergent diseases. Experts say it’s more realistic to develop better drugs instead of attempting to repurpose old ones.</description>
      <content:encoded>
        <![CDATA[BEIJING – While repurposing drugs may be a quick solution to an epidemic like COVID-19 that has a limited research window, it’s just luck as to whether an already available drug candidate exists for newly emergent diseases. Experts say it’s more realistic to develop better drugs instead of attempting to repurpose old ones.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/433445</guid>
      <pubDate>Tue, 03 Mar 2020 12:24:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433445-dont-repurpose-but-develop-better-drugs-experts-say</link>
    </item>
    <item>
      <title>Think of more than just speed in the COVID-19 vaccine race, experts say</title>
      <description>BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced Feb. 24 that it has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released.</description>
      <content:encoded>
        <![CDATA[BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced Feb. 24 that it has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/433444</guid>
      <pubDate>Tue, 03 Mar 2020 12:15:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433444-think-of-more-than-just-speed-in-the-covid-19-vaccine-race-experts-say</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Coronavirus-vaccine-patient.webp?t=1589307546" type="image/png" medium="image" fileSize="465918">
        <media:title type="plain">Man wearing mask, receiving coronavirus vaccine</media:title>
      </media:content>
    </item>
    <item>
      <title>Think of more than just speed in the COVID-19 vaccine race, experts say</title>
      <description>BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced this week it that has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released. That is record speed. Other vaccine developers are also working around the clock to respond to the epidemic.</description>
      <content:encoded>
        <![CDATA[BEIJING – There was encouraging news when vaccine developer Moderna Inc. announced this week it that has shipped the first vials of its mRNA vaccine against COVID-19 for a phase I trial in the U.S. The vaccine was created just 42 days after the genetic sequence of the COVID-19 virus was released. That is record speed. Other vaccine developers are also working around the clock to respond to the epidemic.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/433355</guid>
      <pubDate>Thu, 27 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433355-think-of-more-than-just-speed-in-the-covid-19-vaccine-race-experts-say</link>
    </item>
    <item>
      <title>Don’t repurpose, but develop better drugs, experts say</title>
      <description>BEIJING – While repurposing drugs may be a quick solution to an epidemic like COVID-19 that has a limited research window, it’s just luck as to whether an already available drug candidate exists for newly emergent diseases. Experts say it’s more realistic to develop better drugs instead of attempting to repurpose old ones.</description>
      <content:encoded>
        <![CDATA[BEIJING – While repurposing drugs may be a quick solution to an epidemic like COVID-19 that has a limited research window, it’s just luck as to whether an already available drug candidate exists for newly emergent diseases. Experts say it’s more realistic to develop better drugs instead of attempting to repurpose old ones.]]>
      </content:encoded>
      <guid>http://www.bioworld.com/articles/433327</guid>
      <pubDate>Wed, 26 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433327-dont-repurpose-but-develop-better-drugs-experts-say</link>
    </item>
  </channel>
</rss>
